Internal medicine

Pathology

Placebo

Atrial fibrillation

Double blind

Gastroenterology

Cardiology

Surgery

Warfarin

Alternative medicine

Rivaroxaban

Apixaban

Medicine

The Lancet

The FXIa inhibitor asundexian at doses of 20 mg and 50 mg once daily resulted in lower rates of bleeding compared with standard dosing of apixaban, with near-complete in-vivo FXIa inhibition, in patients with atrial fibrillation.

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study